Epidemiology of carbapenemase producing Enterobacteriaceae in a general hospital

Year 2015, Volume: 5 Issue: 2, 57 - 62, 16.07.2015

Amina Kandeel

https://doi.org/10.5799/ahinjs.02.2015.02.0177

Cited By: 6

Abstract

Objective: Detect the presence of carbapenemases producing Enterobacteriaceae (CPE) and associated epidemiologi­cal, microbiological, and clinical characteristics of patients in our hospital

Methods: During 15 months period, all non duplicate Enterobacteriaceae isolates with reduced susceptibility to car­bapenem detected by MicroScan WalkAway system and confirmed by E test were collected. These suspected isolates were further screened by modified Hodge test and carbapenemase inhibition discs to identify CPE.

Results: Out of 54 suspected Enterobacteriaceae isolates, 44 (88.5%) isolates were either extended spectrum beta-lac­tamases (ESBLs) or AmpC producers with porin loss whereas 10 isolates (18.5%) were confirmed to produce carbapen­emase representing (0.74%) of the total Enterobacteriaceae. Among these 10 isolates, 6 were OXA 48 producers and 2 isolates were class B and class A each. Six out of the 10 CPE were detected in ICU and specimen source was tracheal aspirate in 5 CPE isolates. All CPE isolates were sensitive to colistin and all but one to tigecycline. All patients had history of previous antibiotic exposure and hospital stays for more than 5 days.

Conclusion: Although CPE is not the main cause of carbapenem resistance in Enterobacteriaceae in our setting, its emergence there represents a serious infection control and therapeutic challenge. This mandates its early detection using MHT and carbapenemase inhibition tests together with strict infection control measures to limit its spread. J Mi­crobiol Infect Dis 2015;5(2): 57-62

Amina Kandeel,Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Egyp, Epidemiology of carbapenemase producing Enterobacteriaceae in a general hospital, Amina Kandeel, Department of Medical Microbiology and Immunology, Faculty of Medicine, Mansoura University, Egyp, J Microbiol Infect Dis 2015; 5(2): 57-62 doi: 10.5799/ahinjs.02.2015.02.0177

Key words: Enterobacteriaceae, carbapenemases, resistant organisms, carbapenems, epidemiology

Keywords

Enterobacteriaceae, carbapenemases, resistant organisms, carbapenems, epidemiology

References

• Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant
• Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011;53:60-67.
• Birgy A, Bidet P, Genel N et al. Phenotypic screening of carbapenemases and associated β-lactamases in carbapenem-resistant
• Enterobacteriaceae. J Clin Microbiol 2012;50:1295-1302.
• Nordmann P, Naas T, Poirel L. Global spread of arbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791-1798.
• Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007;20:440-458.
• Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis
• ;9:228-236.
• Navon-Venezia S, Leavitt A, Schwaber MJ, et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumonia in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009;53:818-820.
• Walsh TR, Toleman MA, Poirel L, Nordmannn P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev2005;18:306-325.
• Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae.Antimicrob Agents Chemother 2004;48:15-22.
• Balkhy HH, El-Saed A, Al Johani SM, et al. The epidemiology of
• the first described carbapenem- resistant Klebsiella pneumonia
• outbreak in a tertiary care hospital in Saudi Arabia: how far do we go? Eur. J. Clin. Microbiol. Infect. Dis. 2012; 31:1901-1909.
• Poirel L, Al Maskari Z, Al Rashdi F, et al. NDM-1-producing Klebsiella
• pneumoniae isolated in the Sultanate of Oman. J Antimicrob Chemother 2011;66:304-306.
• Dortet L, Poirel L, Al Yaqoubi F, Nordmann P. NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in Sultanate of Oman. Clin Microbiol Infect 2012;18:E144-E148.
• Maragakis LL. Recognition and prevention of multidrug-resistant
• Gram-negative bacteria in the intensive care unit. Crit Care Med. 2010;38(Suppl 8):S345-351.
• Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenemresistant Klebsiella pneumonia infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol.
• ;29:1099-106.
• Hong T, Moland E, Abdalhamid B, et al. Escherichia coli: development
• of carbapenem resistance during therapy. Clin Infect Dis 2005;40:e84-e86.
• Clinical and Laboratory Standards Institute 2012. Performance
• standards for antimicrobial susceptibility testing: 22nd informational
• supplement. . CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA
• Clinical and Laboratory Standards Institute. 2009. Performance
• standards for antimicrobial susceptibility testing: 20th informational
• supplement. CLSI document M100-S20. Clinical and Laboratory
• Standards Institute, Wayne, PA.
• Carvalhaes CG, Picao RC, Nicoletti AG, et al. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. J Antimicrob Chemother 2010;65:249-251.
• Van Dijk K, Voets GM, Scharringa J, et al. Disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and
• temocillin. Clin Microbiol Infect 2014;20:345-349.
• European Committee on Antimicrobial Susceptibility Testing (EUCAST).Breakpoint tables for interpretation of MICs and zone diameters, version 1.3, January 5, 2011. EUCAST, Växjö, Sweden.
• Kronvall G, Karlsson I, Walder M, et al. Epidemiological MIC cutoff
• values for tigecycline calculated from E test MIC values using normalized resistance interpretation. J Antimicrob Chemother 2006;57:498-505.
• Hara G, Gould I, Endimiani A, et al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International working group. J Chemother
• ;25:129-140.
• Swaminathan M, Sharma S, Blash SP, et al. Prevalence and Risk
• Factors for Acquisition of Carbapenem-Resistant Enterobacteriaceae
• in the Setting of Endemicity. Infect Control Hosp Epidemiol 2013;34:809-817.
• Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial resistant pathogens associated with healthcareassociated
• infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
• Pasteran F, Mendez T, Rapoport M, et al. Controlling false-positive
• results obtained with the Hodge and Masuda assays for detection of class A carbapenemase in species of Enterobacteri-aceaeby incorporating boronic acid. J Clin Microbiol 2010;48:1323-1332.
• Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009; 63:243-245.
• Bartolini A, Frasson I, Cavallaro A, et al. Comparison of phenotypic
• methods for the detection of carbapenem non-susceptible Enterobacteriaceae. Gut Pathog 2014;6:1-7.
• Kandeel A. Prevalence and risk factors of extended-spectrum β-lactamases producing Enterobacteriaceaein a general hospital in Saudi Arabia. J Microbiol Infect Dis 2014; 4:50-54.
• Landman D, Urban C, Backer M, et al. Susceptibility profiles,
• molecular epidemiology, and detection of KPC-producing Escherichia
• coli isolates from the New York City vicinity. J Clin Microbiol
• ;48:4604-4607.
• Endimiani A, Depasquale JM, Forero S, et al. Emergence of blaKPC-containing Klebsiella pneumoniaein a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009;64:1102-1110.
• Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemase:the phantom menace, J. Antimicrob Chemother. 2012;67:1597-1606.
• Shibl A, Al-Agamy M, Memish Z, et al. The emergence of OXA-48- and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia. Int J Infect Dis 2013; 17: e1130-e1133
• Zowawi H, Balkhy H, Walsh T, Patersona D. β-Lactamase Production
• in Key Gram-Negative Pathogen Isolates from the Arabian Peninsula Clin. Microbiol Rev 2013;26:361-380.
• Chitnis AS, Caruthers PS, Rao AK, et al. Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: Sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012;33:984-992.
• Teo J, Cai Y, Tang S, et al. Risk Factors, Molecular Epidemiology
• and Outcomes of Ertapenem-Resistant, Carbapenem-Susceptible Enterobacteriaceae: A Case-Case-Control Study. PLoS One 2012; 7:e34254.